Article
Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir.
Nature - 1 Oct 2023
Duan Yinkai, Zhou Hao, Liu Xiang, Iketani Sho, Lin Mengmeng, Zhang Xiaoyu, Bian Qucheng, Wang Haofeng, Sun Haoran, Hong Seo Jung, Culbertson Bruce, Mohri Hiroshi, Luck Maria I, Zhu Yan, Liu Xiaoce, Lu Yuchi, Yang Xiuna, Yang Kailin, Sabo Yosef, Chavez Alejandro, Goff Stephen P, Rao Zihe, Ho David D, Yang Haitao
Abstract excerpt
Nirmatrelvir is a specific antiviral drug that targets the main protease (Mpro) of SARS-CoV-2 and has been approved to treat COVID-191,2. As an RNA virus characterized by high mutation rates, whether SARS-CoV-2 will develop resistance to nirmatrelvir is a question of concern. Our previous studies have shown that several mutational pathways confer resistance to nirmatrelvir, but some result in a loss of viral...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.